top of page

Cambridge, UK based LoQus23 Therapeutics will use a small molecule allosteric inhibitor of MutSβ to treat Huntington's

19 minutes ago

Co-Founder and CEO David Reynolds describes why LoQus23 is taking a small molecule approach to neurodegenerative diseases and why they believe stopping DNA instability is the right approach to Huntington's and other conditions.

Recent Posts

Cambridge, UK based Harness Therapeutics, which topped up its seed financing this week, aims to use its oligo platform to treat Huntington's by upregulating the FAN1 nuclease across the brain

Akero's CEO comments on today's 96 week MASH data and the future of efruxifermin

IntraBio, which moved from Oxford, UK to Austin, Texas last year, received FDA approval in September for its modified amino acid, AQNEURSA, to treat neurological manifestations of Niemann-Pick type C

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

At Savills, the Life Sciences Team specializes in helping biotech companies unlock their full potential by aligning real estate strategies with their scientific and business goals. As a leading global commercial real estate advisory firm, we focus exclusively on occupier services and tenant representation, acting as a trusted partner to some of the most innovative companies in the industry.

Visit Saville's Life Sciences Overview

bottom of page